Candidat

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, today announcedsignificant progress in validating novel, effective products forthe potential treatment of asthma. In studies of its proprietaryPRS-060 Anticalin(R) candidate, the Company reports that theprotei...

CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) today announced preliminary results ofits randomized, blinded, placebo-controlled clinical trial ofCRx-150 in patients with rheumatoid arthritis (RA). The trialcompared CRx-150 plus a disease-modifying anti-rheumatic drug(DMARD) to placebo plus DMARD (control) in subjects with active RA.In the prelimin...

Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers

BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet,Inc. , a biopharmaceutical company focusing on the development ofnovel, proprietary antibody-based products for cancer, inflammatoryand autoimmune diseases, announced that a study published recentlyin the Proceedings of the National Academy of Sciences (1) supportsthe findings of several other studies that EpCAM (CD326), whic...

Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection

SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ -- AnadysPharmaceuticals, Inc. , a biopharmaceutical company committed tothe discovery, development and commercialization of novel medicinesfor the treatment of hepatitis and cancer, announced today that ithas nominated ANA598 as a candidate for clinical development as anorally-administered direct antiviral for the treatment of chronichepat...

Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 14, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) today announced the presentation ofadditional data related to its immuno-inflammatory productcandidates, CRx-102 and CRx-139, at the European League AgainstRheumatism (EULAR) Annual Congress of Rheumatology meeting, June13-16, 2007 in Barcelona, Spain. In a poster entitled "Inhibition...

Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX), today announced that data from itsrandomized, blinded, placebo-controlled phase 2 clinical trials ofCRx-102 in patients with osteoarthritis (OA) and rheumatoidarthritis (RA) will be featured at the European League againstRheumatism (EULAR) Annual Congress of Rheumatology meeting, June13-16, 2007 in Bar...

Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Society's Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Metabasis Therapeutics,Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on thediscovery, development and commercialization of novel drugs for thetreatment of metabolic and liver diseases by applying uniquecapabilities for targeting the liver and liver pathways, announcedtoday that two posters were presented at the Endocrine Society's89th Annu...

Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age

New Study Results Show Antibodies Against Cancer-Causing VirusTypes 16 & 18 That Are At Least Ten Times Greater Than NaturalInfection Levels CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data showthat at 18 months after the first of a three-dose regimen, 100percent of women up to age 55 vaccinated with the GlaxoSmithKline(GSK) cervical cancer candidate vaccine had antibodies pr...

Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201

Both Co-Primary Endpoints, Wake After Sleep Onset and Total SleepTime, and Key Secondary Endpoints, Including Latency to PersistentSleep, Were Met at Both Doses HAMBURG, Germany and OXFORD, England, June 04, 2007/PRNewswire-FirstCall/ -- Evotec AG announced today positivetop-line results from its first phase II clinical trial of EVT 201in patients with chronic primary insomnia. EVT 201 is...

LifeCycle Pharma Announces Positive Phase I Clinical Results for its Transplantation Product Candidate, LCP-Tacro

Heads into US Phase II Clinical Trials for Organ Transplantation HORSHOLM, Denmark, May 31, 2007 /PRNewswire-FirstCall/ --LifeCycle Pharma announces positive Phase I clinical results forits transplantation product candidate, LCP-Tacro - Heads into USPhase II clinical trials for organ transplantation. Today LifeCycle Pharma A/S (OMX:LCP) announces positive resultsfrom its Phase I cli...

Synta Oncology Candidate STA-4783 Clinical Trial Results to Be Presented at the ASCO Annual Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--May 23, 2007 - SyntaPharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical companyfocused on discovering, developing, and commercializing smallmolecule drugs to treat severe medical conditions, today announcedthat survival and sub-population data from the Phase 2b clinicaltrial in metastatic melanoma of the Company's lead oncology drugcandidate, STA-478...

VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models

MALAGA, Spain--(BUSINESS WIRE)--May 23, 2007 - VGX Pharmaceuticals'novel pandemic influenza vaccine candidates triggered protectiveimmune responses in pre-clinical challenge studies, according todata presented for the first time today at the Third InternationalConference on DNA Vaccines in Malaga, Spain. VGX scientists created four synthetic consensus DNA vaccines toprotect against a leth...

Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug Candidate, Sphingomab

Sphingomab Shows Near-Complete Mitigation of ChoroidalNeovascularization (CNV) in an AMD Model SAN DIEGO, May 22, 2007 /PRNewswire-FirstCall/ -- Lpath, Inc. ,the category leader in therapeutic agents against bioactive lipids,reported compelling proof-of-concept data in a standard animalmodel of human age-related macular degeneration (AMD). The results were presented at the annual me...

Data to be presented at AAN Meeting -Study results of drug candidate for MS

Preclinical Studies Suggest FTY720 Mechanisms in MultipleSclerosis May Include Direct Activity in the Brain · Preclinical studies suggest FTY720 stimulates cellsthat may help reduce neurodegeneration and enhance repair of theCNS affected by multiple sclerosis · Separately, analyses from the six-month multiplesclerosis Phase II clinical study found that the propo...

EPIX Pharmaceuticals Announces Statistically Significant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - EPIXPharmaceuticals, Inc. (NASDAQ: EPIX) announced today positivecognitive function results from its Phase 1b multiple ascendingdose clinical trial of PRX-07034, the company'sinternally-discovered, novel 5-HT6 antagonist being developed forobesity, Alzheimer's disease and cognitive impairment associatedwith schizophrenia. The randomized,...

Adnexus Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) on Clinical Product Candidate, CT-322

WALTHAM, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Adnexus(TM)Therapeutics, Inc. today announced the presentation of the abstract"CT-322: A specific VEGFR-2-blocking protein therapeutic agent withactivity in preclinical tumor models comparable to pan-specifictyrosine kinase receptor inhibitors sunitinib and sorafenib" at theAmerican Association for Cancer Research (AACR) 2007 annual meetingin...

Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years

New study results also show evidence of additional protectionagainst infection with other cancer-causing virus types LOS ANGELES, April 17, 2007 /PRNewswire-FirstCall/ -- TheGlaxoSmithKline cervical cancer candidate vaccine, CERVARIX(R),demonstrated 100 percent efficacy in preventing precancerouslesions due to cancer-causing human papillomavirus types 16 and 18for up to 5.5 years in an ex...

Lorus Therapeutics Announces Scientific Presentations for Lead Antisense and siRNA Drug Candidates at International Cancer Conference

98th Annual Meeting of the American Association for Cancer Research(AACR) TORONTO, April 17, 2007 /PRNewswire-FirstCall/ - LorusTherapeutics Inc. ("Lorus") today announced presentation ofresearch on their lead antisense and siRNA compounds at the 98thAnnual Meeting of the AACR in Los Angeles, CA, April 14-18,2007. The first presentation titled, "Determination of optimizedadministr...

Biomira Selects PX-866 as Clinical Development Candidate and Presents Promising Preclinical Data at AACR

-IND filing expected by end of 2007- EDMONTON, April 16, 2007 /PRNewswire-FirstCall/ - Biomira Inc.today announced that it has selected PX-866 as its next clinicaldevelopment candidate. PX-866 is an inhibitor of thephosphatidylinositol-3-kinase (PI3 kinase)/ PTEN/AKT pathway, animportant survival signaling pathway that is activated in manytypes of human cancer, including glioblastoma. Pre...

Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - Arrowhead ResearchCorporation (NASDAQ: ARWR) announced the publication by itsmajority-owned subsidiary Calando Pharmaceuticals, Inc. of a studydemonstrating the anti-proliferative effect of the siRNA sequenceselected as the therapeutic component of its lead anti-cancercompound, CALAA-01. The paper, entitled "Potent siRNA Inhibitors of Ribon...

Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - CalandoPharmaceuticals, a leading siRNA therapeutics company and amajority-owned subsidiary of Arrowhead Research Corporation(NASDAQ:ARWR) announced the publication of a study demonstratingthe anti-proliferative effect of the siRNA sequence selected as thetherapeutic component of its lead anti-cancer compound, CALAA-01. The paper, entitled...

Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine

DEERFIELD, Ill., March 29, 2007 /PRNewswire-FirstCall/ -- BaxterInternational Inc. today announced final Phase I/II data for itsadjuvant-free investigational pandemic H5N1 influenza vaccine andplans to initiate a Phase III clinical trial of the candidatevaccine in Europe to confirm the study results. The Phase I/II study indicated that Baxter's H5N1 candidatevaccine is highly immun...

Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation

Novel Approach to Address Growing Problem of Antibiotic ResistancePublished in Nature Biotechnology VANCOUVER, British Columbia, March 26, 2007 /PRNewswire/ --Inimex Pharmaceuticals Inc.'s product candidate IDR-1 is the firstimmune system trigger to cure infections without causing harmfulinflammation, according to a paper published in the April 2007issue of Nature Biotechnology. Th...